Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Iovance Biotherapeutics, Inc.

http://www.iovance.com/

Latest From Iovance Biotherapeutics, Inc.

ASCO: Presentations Showcase Possibilities Of Next-Generation Cell Therapies

An education session looked at ways researchers are hoping to make cell therapies more applicable in solid tumors.

ASCO ImmunoOncology

Tech Transfer: BMS, Evotec Partner With Four UK Universities On Translational Research Efforts

The firms hope academic research can yield first-in-class therapies and spinout companies. Also, Yale unveils research alliances with three biotechs.

Tech Transfer Deals Deals

Adaptimmune ‘Neck And Neck’ For First Solid Tumor T-Cell Therapy Nod For Afami-Cel

The company’s CEO and chief medical officer talked about some challenges as well as opportunities and what they have learned from the experience of other cell therapies.

ASCO Biologics

CEO Exit Adds To Iovance Woes After Cell Therapy Setback

Iovance has a promising new cancer cell therapy on its hands, but another FDA query and the CEO’s departure has spooked investors.

Commercial Companies
See All

Company Information

  • Industry
  • Biotechnology
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Other Names / Subsidiaries
    • Genesis Biopharma
    • Lion Biotechnologies, Inc. (LBIO)
UsernamePublicRestriction

Register